Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Exelixis Defends Cancer Drug XL184 After Partner BMS Walks Out

This article was originally published in The Pink Sheet Daily

Executive Summary

After spending $257 million and pushing into Phase III trials for a rare thyroid cancer, Bristol-Myers Squibb ends its deal. Exelixis CEO George Scangos says: "There is no smoking gun."

You may also be interested in...

In 2012, Buyer’s Market Made Alliances Rarer

With little leverage against Big Pharma, some smaller companies are turning away from long-standing partnering strategies. It’s one reason dealmaking slowed considerably in 2012, part of a three-year trend that also highlights increasing reliance on heavily structured partnerships.

Exelixis’ Cabozantinib Targets Particularly Sick Thyroid Cancer Patients

Progression-free survival benefit in Phase III trial of rare medullary thyroid cancer was even better than expected, though full safety results are needed to flesh out the drug’s profile.

Will Exelixis’ Cabozantinib Miss The Boat In Prostate Cancer?

Exelixis says one pain study may do it for approval, despite losing an SPA with FDA and the agency’s preference for an overall survival endpoint.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts